|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.00 GBX | -0.44% |
|
-5.86% | +8.17% |
| 14/01 | Hutchmed China hails lung cancer trial results published in Lancet | AN |
| 14/01 | HUTCHMED Limited Highlights Publication of Phase III SACHI Results in the Lancet | CI |
| Capitalization | 262.52Cr 223.27Cr 206.95Cr 193.39Cr 360.52Cr 24TCr 382.12Cr 2.37TCr 938.97Cr 11TCr 984.36Cr 964.23Cr 41TCr | P/E ratio 2025 * |
6.04x | P/E ratio 2026 * | 45.4x |
|---|---|---|---|---|---|
| Enterprise value | 199.86Cr 169.98Cr 157.56Cr 147.24Cr 274.48Cr 18TCr 290.92Cr 1.8TCr 714.87Cr 8.67TCr 749.43Cr 734.1Cr 32TCr | EV / Sales 2025 * |
3.41x | EV / Sales 2026 * | 2.67x |
| Free-Float |
57.51% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: HUTCHMED (China) Limited
| 1 day | -0.44% | ||
| 1 week | -5.86% | ||
| Current month | +8.17% | ||
| 1 month | +16.58% | ||
| 3 months | -1.75% | ||
| 6 months | -14.29% | ||
| Current year | +8.17% |
| 1 week | 221 |  | 239 |
| 1 month | 192 | | 239 |
| Current year | 194 | | 239 |
| 1 year | 185.5 | | 292 |
| 3 years | 173.6 | | 353 |
| 5 years | 130 | | 656 |
| 10 years | 130 | | 656 |
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 25/08/2025 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2022 |
Karen Atkin
COO | Chief Operating Officer | 60 | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 01/01/2006 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 01/01/2011 |
Wei Guo Su
BRD | Director/Board Member | 68 | 27/03/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.07% | 0.01% | 33,076 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.44% | -5.86% | +2.27% | -24.37% | 262.52Cr | |
| -2.12% | +2.49% | +38.83% | +211.00% | 95TCr | |
| +0.76% | +0.68% | +50.12% | +30.79% | 53TCr | |
| +0.53% | +2.29% | +28.47% | +47.60% | 39TCr | |
| +0.06% | -0.23% | +26.86% | +17.82% | 38TCr | |
| +0.15% | -3.36% | +22.94% | +23.03% | 29TCr | |
| +0.47% | +0.03% | +28.12% | +35.36% | 28TCr | |
| +1.17% | +3.20% | -30.92% | -16.86% | 28TCr | |
| -0.92% | -0.60% | +11.95% | -1.55% | 27TCr | |
| -0.67% | +4.34% | +24.06% | +32.10% | 19TCr | |
| Average | -0.10% | +0.08% | +20.27% | +35.49% | 35.53TCr | |
| Weighted average by Cap. | -0.35% | +0.91% | +27.64% | +73.14% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 59Cr 50Cr 46Cr 43Cr 81Cr 5.39TCr 85Cr 528.81Cr 209.94Cr 2.55TCr 220.09Cr 215.59Cr 9.26TCr | 69Cr 59Cr 55Cr 51Cr 95Cr 6.37TCr 100.95Cr 624.86Cr 248.07Cr 3.01TCr 260.07Cr 254.75Cr 11TCr |
| Net income | 40Cr 34Cr 32Cr 30Cr 55Cr 3.71TCr 59Cr 363.82Cr 144.44Cr 1.75TCr 151.42Cr 148.32Cr 6.37TCr | 6.41Cr 5.45Cr 5.05Cr 4.72Cr 8.8Cr 588.47Cr 9.32Cr 58Cr 23Cr 277.85Cr 24Cr 24Cr 1.01TCr |
| Net Debt | -63Cr -53Cr -49Cr -46Cr -86Cr -5.76TCr -91Cr -564.47Cr -224.1Cr -2.72TCr -234.93Cr -230.13Cr -9.89TCr | -77Cr -66Cr -61Cr -57Cr -105.98Cr -7.09TCr -112.33Cr -695.26Cr -276.02Cr -3.35TCr -289.37Cr -283.45Cr -12TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 225.00 p | -0.44% | 2,98,132 |
| 22/26/22 | 226.00 p | +0.44% | 1,03,636 |
| 21/26/21 | 225.00 p | 0.00% | 88,508 |
| 20/26/20 | 225.00 p | -3.23% | 2,361 |
| 19/26/19 | 232.50 p | -2.72% | 1,599 |
Delayed Quote London S.E., January 23, 2026 at 10:05 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HCM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition